Merck Gets EU Approval of Expanded Keytruda Use in Melanoma
24 Juni 2022 - 01:29PM
Dow Jones News
By Colin Kellaher
Merck & Co. on Friday said the European Commission approved
the expanded use of its blockbuster cancer drug Keytruda for
certain patients with melanoma, the most serious form of skin
cancer.
The Kenilworth, N.J., drugmaker said Keytruda is now approved as
monotherapy for the treatment of people ages 12 and older with
stage IIB or IIC melanoma and who have undergone complete
resection.
Merck said the commission also approved expanding the
indications for Keytruda in advanced melanoma and stage III
melanoma, as adjuvant treatment following complete resection, to
include adolescent patients ages 12 and up.
Keytruda, a cancer drug that harnesses a patient's immune system
to fight tumors, is approved in dozens of indications around the
world. Sales of the drug topped $17 billion last year.
Write to Colin Kellaher at colin.kellaher@wsj.com
(END) Dow Jones Newswires
June 24, 2022 07:14 ET (11:14 GMT)
Copyright (c) 2022 Dow Jones & Company, Inc.
Merck (NYSE:MRK)
Historical Stock Chart
Von Feb 2024 bis Mär 2024
Merck (NYSE:MRK)
Historical Stock Chart
Von Mär 2023 bis Mär 2024